In Brief: Boston Scientific/CorTrak
This article was originally published in The Gray Sheet
Boston Scientific/CorTrak: Boston Scientific gains exclusive international distribution rights to CorTrak's coronary iontophoresis drug delivery technology. CorTrak's technology, currently in clinical trials, will initially be used for treating and/or preventing angioplasty associated complications. The system "uses a catheter and an electronic field to transport drugs through difficult tissue barriers and into the cells...more quickly and deeply than conventional drug delivery systems," CorTrak says...
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.